Status: Ongoing
First registered on:
09/02/2017
Last updated on:
09/02/2017
1. Study identification
EU PAS Register NumberEUPAS17776
Official titleIncretin‐based drugs and Retinopathy risk in Medicare Enrollees
Study title acronym
Study typeObservational study
Brief description of the studyThis will be a retrospective cohort study using a new-user active comparator design on Medicare Part A, B and D claims data from 2006-2014. The study population consists of Medicare enrollees initiating incretin-based drugs (GLP-1 receptor agonists or DPP-4 inhibitors) or other antidiabetic drugs (thiazolidinediones, sulfonylureas or long-acting insulins). New users of incretin-based drugs and other antidiabetic drugs will be compared with respect to the incidence of retinopathy, adjusted for baseline information collected prior to drug initiation.
Was this study requested by a regulator?No
Is the study required by a Risk Management Plan (RMP)?
Not applicable
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Centre nameDepartment of Epidemiology, University of North Carolina at Chapel Hill
Centre locationChapel Hill, North Carolina, United States
Details of (Primary) lead investigator
Title Dr
Last name Stürmer
First name Til
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Not applicable (single centre)
Countries in which this study is being conducted
National study
United States
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed09/02/201709/02/2017
Start date of data collection09/02/201709/02/2017
Start date of data analysis09/02/201709/02/2017
Date of interim report, if expected
Date of final study report28/02/2018
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companies
Charities
Government body
Research councils
EU funding scheme
OtherUnfunded100
5. Contact details for enquiries
Scientific Enquiries
Title Dr
Last name Stürmer
First name Til
Address line 1135 Dauer Drive, CB# 7435
Address line 2
Address line 3
CityChapel Hill, NC
Postcode27599
CountryUnited States
Phone number (incl. country code)001-9199667433
Alternative phone number
Fax number (incl. country code)
Public Enquiries
Title Dr
Last name Stürmer
First name Til
Address line 1135 Dauer Drive, CB# 7435
Address line 2
Address line 3
CityChapel Hill, NC
Postcode27599
CountryUnited States
Phone number (incl. country code)001-9199667433
Alternative phone number
Fax number (incl. country code)
6. Study drug(s) information
Substance class (ATC Code)A10 (DRUGS USED IN DIABETES)
7. Medical conditions to be studied
Medical condition(s)Yes
Retinopathy
Diabetes mellitus
8. Population under study
Age
Adults (65 - 74 years)
Adults (75 years and over)
Sex
Male
Female
9. Number of subjects
Estimated total number of subjects350000
10. Source of data
Is this study being carried out with an established data source?Yes
Data sources not registered with ENCePP
20% random sample of Medicare claims data from 2007-2012, United States, United States
Sources of data
Administrative database, e.g. claims database
11. Scope of the study
What is the scope of the study?
Risk assessment
Primary scope : Risk assessment
12. Main objective(s)
What is the main objective of the study?
To examine the effect of initiation of incretin‐based therapies (IBRx) relative to other antidiabetic therapies (CompRx) on the incidence of retinopathy based on an active comparator new‐user study design.
Are there primary outcomes?Yes
Incident Retinopathy
Are there secondary outcomes?No
13. Study design
What is the design of the study?
Cohort study
14. Follow-up of patients
Will patients be followed up?Not applicable/no follow-up
15. Data analysis plan
Please provide a brief summary of the analysis method
IBRx new-users will be compared with new users of CompRx with respect to incidence of retinopathy diagnosis. We will use propensity scores to balance measured risk factors for retinopathy between these cohorts. Hazard rates for retinopathy will be estimated using a Cox proportional hazards model controlling for age and sex as well as any covariates remaining imbalanced after implementation of the propensity score.
16. ENCePP seal
Are you requesting the ENCePP seal for this study?
No
17. Full protocol
Available when the study ends
18. Study Results
Not submitted
Please list the 5 most relevant publications using data from your study
ReferenceLink to web-publication
None
19. Other relevant documents
Conflict(s) of interest of
investigator(s)Not submitted
Composition of Steering Group and
ObserversNot submitted
Other documentsNot
submitted
Signed Code of
Conduct Checklist
Not submitted
Signed Code of Conduct Declaration
Not submitted
Signed Checklist for Study
Protocols
Not submitted
